▴ Infliximab is a monoclonal antibody that binds to tumour necrosis factor-α and blocks its biological activity. It is approved for use in patients with rheumatoid arthritis, Crohn’s disease and ankylosing spondylitis.
▴ In well designed, placebo-controlled trials of 12 or 24 weeks’ duration in patients with active ankylosing spondylitis, more infliximab 5 mg/kg recipients achieved a response than placebo recipients according to Ankylosing Spondylitis Assessment Study 20% (61.2% vs 19.2%) or Bath Ankylosing Spondylitis Disease Activity Index 50% (53% vs 9%) criteria (primary endpoints).
▴ Infliximab was also superior to placebo in terms of various secondary clinical endpoints and in reducing spinal inflammation (as assessed by magnetic resonance imaging).
▴ Prolonged efficacy has been demonstrated in patients with ankylosing spondylitis who received infliximab for up to 3 years.
▴ Infliximab is generally well tolerated in patients with ankylosing spondylitis, with most adverse events being of mild-to-moderate severity.
Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn’s disease and rheumatoid arthritis. Biodrugs 2002; 16(2): 111–48PubMedCrossRefGoogle Scholar
Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003 Sep; 62(9): 817–24PubMedCrossRefGoogle Scholar
Braun J, Xiang J, Brandt J, et al. Treatment of spondyloarthropathies with antibodies against tumour necrosis factor α: first clinical and laboratory experiences. Ann Rheum Dis 2000; 59 Suppl. 1: i85–9PubMedCrossRefGoogle Scholar
Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNF-α, IL-1β and IFN-γ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994 Oct; 33(10): 927–31PubMedCrossRefGoogle Scholar
Zou JX, Braun J, Sieper J. Immunological basis for the use of TNFα-blocking agents in ankylosing spondylitis and immunological changes during treatment. Clin Exp Rheumatol 2002 Nov–Dec; 20 (6 Suppl. 28): S34–7PubMedGoogle Scholar
Wagner C, Mace K, deWoody K. Infliximab treatment benefits correlate with pharmacodynamic parameters in Crohn’s disease patients. Digestion 1998; 59 Suppl. 3: 124–5Google Scholar
Zou J, Rudwaleit M, Brandt J, et al. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003; 48(3): 780–90PubMedCrossRefGoogle Scholar
Baeten D, Vandooren B, De Rycke L, et al. Effect of infliximab treatment on T cell cytokine responses in spondylarthropathy: comment on the article by Zou et al. [letter]. Arthritis Rheum 2004; 50(3): 1015–7PubMedCrossRefGoogle Scholar
Yang C, Gu J, Rihl M, et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004 Oct; 51(5): 691–9PubMedCrossRefGoogle Scholar
Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994 Dec; 21(12): 2286–91PubMedGoogle Scholar
Vandooren B, Kruithof E, Yu DT, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor α blockade in spondylarthropathy. Arthritis Rheum 2004 Sep; 50(9): 2942–53PubMedCrossRefGoogle Scholar
Boyle A, Tawadros R, Zhu Y, et al. Comparative pharmacokinetics of single and multiple-dose infliximab in Crohn’s disease patients [abstract no. W1349]. Gastroenterology 2002 Apr; 122 Suppl. 1: A614–5. Plus poster presented at Digestive Disease Week and the 103rd Annual Meeting of the American Gastroenterological Association; 2002 May 19–23; San FranciscoGoogle Scholar
Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998 Sep; 41(9): 1552–63PubMedCrossRefGoogle Scholar
Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002 Apr 6; 359: 1187–93PubMedCrossRefGoogle Scholar
van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005 Feb; 52(2): 582–91PubMedCrossRefGoogle Scholar
Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003 Apr; 48(4): 1126–36PubMedCrossRefGoogle Scholar
Braun J, Landewé R, Hermann K-G, et al. The effect of infliximab therapy on spinal inflammation assessed by magnetic resonance imaging in a randomized, placebo-controlled trial of 279 patients with ankylosing spondylitis [abstract no. L21]. Presented at 68th Annual Meeting of the American College of Rheumatology; 2004 Oct 16–21; San Antonio [online]. Available from URL: http://www.rheumatology.org/annual/abstracts/search.asp [Accessed 2005 May 11]
Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003 Aug; 48(8): 2224–33PubMedCrossRefGoogle Scholar
Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005 Feb; 64(2): 229–34PubMedCrossRefGoogle Scholar
Braun J, Baraliakos X, Brandt J, et al. Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005 May; 44(5): 670–6CrossRefGoogle Scholar
Baraliakos X, Brandt J, Listing J, et al. Clinical response to withdrawal of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Clin Exp Rheumatol 2004 Sep–Oct; 22(5): 665Google Scholar
Stone M, Salonen D, Lax M, et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001 Jul; 28: 1605–14PubMedGoogle Scholar
Stone MA, Payne U, Pacheco-Tena C, et al. Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 2004 Jan; 63(1): 84–7PubMedCrossRefGoogle Scholar
Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 2002 Nov; 41: 1280–5CrossRefGoogle Scholar
Temekonidis TI, Alamanos Y, Nikas SN, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003 Dec; 62(12): 1218–20PubMedCrossRefGoogle Scholar
Kobelt G, Andlin-Sobocki P, Brophy S, et al. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade®). Rheumatology (Oxford) 2004 Sep; 43(9): 1158–66CrossRefGoogle Scholar
Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994 Dec; 21(12): 2281–5PubMedGoogle Scholar
Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001 Aug; 44(8): 1876–86PubMedCrossRefGoogle Scholar
Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994 Sep; 21(9): 1694–8PubMedGoogle Scholar
Ferraro-Peyret C, Coury F, Tebib JG, et al. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 2004; 6(6): R535–43PubMedCrossRefGoogle Scholar